OneVentures
Australia's Employment Hero raises Series F at $1.3b valuation
Australian human resources start-up Employment Hero has achieved a valuation of approximately AUD 2bn (USD 1.3bn) on closing a AUD 263m Series F round led by US-based venture capital firm TCV.
Australian needle-free vaccine start-up raises $23m
OneVentures and UniQuest have led a AUD 34m (USD 23m) funding round for Vaxxas, an Australia-based biotechnology company running clinical programmes that include a needle-free COVID-19 vaccine candidate.
GPs seek alternatives in absence of US IPOs – AVCJ Forum
Private markets investors have responded to the drop-off in US IPO activity by exploring listings within Asia, while M&A is expected to play a more important role, the AVCJ Private Equity & Venture Forum heard.
Australia retail AI player raises $30m
Tiger Global Management has led a USD 30m Series B round for Australia’s Hivery, an artificial intelligence (AI) developer for the retail industry.
Australia tech: Valuation conundrum
Valuation adjustments and down rounds are expected to proliferate in Australia’s technology sector in the next 12 months. Investors are busy scrutinising business models for signs of vulnerability
Bond leads $43m Series C for Australia's Eucalyptus
Bond, a US-based technology investment firm established by Silicon Valley stalwart Mary Meeker, has led a AUD 60m (USD 43m) Series C round for Australian telehealth platform Eucalyptus.
Insight leads Series E for Australia's Employment Hero
Insight Partners has led a $140 million Series E round for Australian human resources services start-up Employment Hero at a valuation of $800 million.
Australia's Employment Hero gets $35m Series D
Australian online human resources services start-up Employment Hero has raised A$45 million ($35 million) in Series D funding led by domestic recruitment business Seek.
Australia's OneVentures closes credit fund at $57m
OneVentures has reached a final close of A$80 million ($57 million) on a venture debt fund said to be the first and largest vehicle of its kind in Australia.
Women in PE: Mind the gap
Gender diversity within private equity is an increasing priority for LPs and GPs alike. Addressing problems around the recruitment and retention of women requires fundamental changes in culture and mindset
OneVentures, AirTree in $15m round for Australia HR platform
Australia’s OneVentures and AirTree Ventures have joined online jobs marketplace Seek in a A$22 million ($15.3 million) Series C round for local human resources platform Employment Hero.
Australia's OneVentures hits $32m first close on venture debt fund
Australia’s OneVentures has reached a A$45 million ($32 million) first close on a venture debt fund touted as the first of its kind in the country.
Mixed impact on exits as early-stage VC heats up – AVCJ Forum
VCs face new challenges and opportunities in exit markets across Asia as later-stage investors and strategic players participate more deeply in early-stage ecosystems.
Australia's OneVentures launches $74m venture debt fund
Australia’s OneVentures has partnered with Israel-based Viola Credit to launch a A$100 million ($74 million) venture debt fund that is said to be the first vehicle of its kind in Australia.
Profile: OneVentures' Michelle Deaker
OneVentures co-founder Michelle Deaker leveraged a background of IT innovation to introduce a much-needed dose of entrepreneurialism into the early days of Australia’s venture capital industry
Technology: The unavoidable angle
Technology is directly or indirectly redefining business models across Asia. Private equity investors must embrace change or risk seeing returns damaged as portfolio companies are disrupted
Succession planning: Ending an era
Succession planning is quickly becoming a strategic priority across Asia Pacific. In Australia, GPs are looking into a number of different ways to make it work
OneVentures invests $7.4m in Australia’s Prota Therapeutics
Australia’s OneVentures has invested A$10 million ($7.4 million) in Prota Therapeutics, a domestic immunotherapy technology developer aiming to commercialize new peanut allergy treatments for children.